Early pregnancy probiotic supplementation with Lactobacillus rhamnosus HN001 may reduce the prevalence of gestational diabetes mellitus: a randomised controlled trial. Issue 6 (3rd April 2017)

• Record Type: Journal Article
• Authors: Wickens, Kristin L.; Barthow, Christine A.; Murphy, Rinki; Abels, Peter R.; Maude, Robyn M.; Stone, Peter R.; Mitchell, Edwin A.; Stanley, Thorsten V.; Purdie, Gordon L.; Kang, Janice M.; Hood, Fiona E.; Rowden, Judy L.; Barnes, Phillipa K.; Fitzharris, Penny F.; Crane, Julian
• Is Part Of: British journal of nutrition. Volume 117:Issue 6(2017)
• Page Start: 804
• Page End: 813
• Publication Date: 2017-04-03
• Subjects: Randomised controlled trials, -- Probiotics, -- Lactobacillus rhamnosus HN001, -- Gestational diabetes mellitus; Nutrition -- Periodicals; 572.4
• DOI: 10.1017/S0007114517000289
• Languages: English
• ISSNs: 0007-1145

Abstract

Abstract: The study aims to assess whether supplementation with the probiotic Lactobacillus rhamnosus HN001 (HN001) can reduce the prevalence of gestational diabetes mellitus (GDM). A double-blind, randomised, placebo-controlled parallel trial was conducted in New Zealand (NZ) (Wellington and Auckland). Pregnant women with a personal or partner history of atopic disease were randomised at 14–16 weeks' gestation to receive HN001 (6×10 9 colony-forming units) ( n 212) or placebo ( n 211) daily. GDM at 24–30 weeks was assessed using the definition of the International Association of Diabetes and Pregnancy Study Groups (IADPSG) (fasting plasma glucose ≥5·1 mmol/l, or 1 h post 75 g glucose level at ≥10 mmol/l or at 2 h ≥8·5 mmol/l) and NZ definition (fasting plasma glucose ≥5·5 mmol/l or 2 h post 75 g glucose at ≥9 mmol/l). All analyses were intention-to-treat. A total of 184 (87 %) women took HN001 and 189 (90 %) women took placebo. There was a trend towards lower relative rates (RR) of GDM (IADPSG definition) in the HN001 group, 0·59 (95 % CI 0·32, 1·08) ( P =0·08). HN001 was associated with lower rates of GDM in women aged ≥35 years (RR 0·31; 95 % CI 0·12, 0·81, P =0·009) and women with a history of GDM (RR 0·00; 95 % CI 0·00, 0·66, P =0·004). These rates did not differ significantly from those of women without these characteristics. Using the NZ definition, GDM prevalence was significantly lower in the HN001 group, 2·1 % (95 % CI 0·6, 5·2), v . 6·5 % (95 % CI 3·5, 10·9) in the placebo group ( P =0·03). HN001 supplementation from 14 to 16 weeks' gestation may reduce GDM prevalence, particularly among older women and those with previous GDM.